Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial [Yahoo! Finance]
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events [Yahoo! Finance]
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events